首页> 外文期刊>Seminars in radiation oncology >Progress in Low Dose Rate Brachytherapy for Prostate Cancer
【24h】

Progress in Low Dose Rate Brachytherapy for Prostate Cancer

机译:前列腺癌低剂量率近距离放射治疗的进展

获取原文
获取原文并翻译 | 示例
       

摘要

Low dose rate (LDR) brachytherapy has a proven critical role in achieving the modern standard of successful prostate cancer treatment, cure with quality of life (QoL) preservation. In the past decade, cure has been demonstrated in the most lethal form of prostate cancer treated with combined external beam and LDR brachytherapy. Additionally, QoL has moved from toxicity avoidance to preservation of function, with unprecedented sexual function preservation proven with intensive combination therapy. The technical advances that have made such outcomes possible have defined the full, dynamic complexity of the permanent prostate implant procedure, as well as effective solutions. Progress in LDR brachytherapy as it relates to prostate cancer biology, local control, toxicity reduction with function preservation, external beam integration, medical event prevention, patient selection, and comparative brachytherapy is reviewed. As in all brachytherapy procedures, the final clinical outcomes of cure, and QoL depend entirely on a foundation of verifiable technical excellence. (C) 2019 The Authors. Published by Elsevier Inc.
机译:低剂量率(LDR)近距离放射治疗在实现现代成功前列腺癌症治疗标准方面具有证明关键作用,治愈了生活质量(QOL)保存。在过去的十年中,治愈了用组合的外梁和LDR近距离放射治疗治疗的最致命的前列腺癌。此外,QOL已经从毒性避免旋转,以保存功能,具有前所未有的性功能保存,并具有密集的组合治疗。使这种结果可能的技术进步已经确定了永久性前列腺植入程序以及有效的解决方案的完整动态复杂性。 LDR近距离放射治疗的进展与前列腺癌生物学,局部控制,毒性降低函数保存,外梁整合,医疗预防,患者选择和对比近距离放射治疗。与所有近距离放射治疗程序一样,治疗的最终临床结果,QOL完全取决于可核实技术卓越的基础。 (c)2019年作者。 elsevier公司发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号